reference/22994714

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/22994714

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	580
issn	1470-2045
issueIdentifier	4
pageRange	571-580
publicationName	The Lancet. Oncology
startingPage	571
bibliographicCitation	Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, Lin X, Chen X, Li E, Wang L, Chen C, Zou J. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020 Apr;21(4):571–80. doi: 10.1016/s1470-2045(20)30011-5. PMID: 32112738.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-7160-9241 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fbb3aad70baec7bacf12573951be1bba http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bbf60ecf6c3dde1cb62b2f58c3e39651 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ab3085b763887a35907bad4ca3a9f1e1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_76cc40a32669b56e91d62b4716c5cc49 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cc8053e8cc6666ff7702f34ac4a21358 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5d4addc75c0e32ac18dc6e0aca595e33 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f749cfdca0d90dd1b6d4e4932dc98ecc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_18fc094c9db09c5a8183176097560116 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1ab80c85e05ca9b49bad1efc4a130f80 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5cb80f4faee87301bb435e25707e766a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1e963f44ca67ea78601671a95e686de1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_77c72e1d8553594bf5b0f685d1a947ac http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6bced3033bbc0b3c3c609ee9cbb54989 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_edb111f5c21e55a38254c6477df048ab http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8c14e669ce16e0b3dcd989fc84b37a30 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e5ebbc759d6863732a6281d18c33ae12 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-5085-6761
date	202004
identifier	https://doi.org/10.1016/s1470-2045%2820%2930011-5 https://pubmed.ncbi.nlm.nih.gov/32112738
isPartOf	https://portal.issn.org/resource/ISSN/1470-2045 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/27004
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
discusses	http://id.nlm.nih.gov/mesh/M000651317 http://id.nlm.nih.gov/mesh/M0556300
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D061067Q000627 http://id.nlm.nih.gov/mesh/D008113Q000188 http://id.nlm.nih.gov/mesh/D006528Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008297
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.6.1.1 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8349 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7998 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b83d04d3e3b05ce10d1a5893dc850a9b http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8531

Total number of triples: 51.